Literature DB >> 6518450

The mitochondrial genetic system as a target for chemotherapy: tetracyclines as cytostatics.

A M Kroon, B H Dontje, M Holtrop, C Van den Bogert.   

Abstract

The mitochondrial genetic system is indispensable for the biosynthesis of the enzyme complexes involved in aerobic energy generation. Tetracyclines inhibit the expression of only the mitochondrial genes because they specifically block mitochondrial protein synthesis. A salient feature is that this inhibition occurs at the low concentration required for anti-bacterial treatment, provided that this concentration is maintained continuously. Evidence is presented that the growth of carcinogen-induced tumors can be inhibited by tetracyclines. It is further shown that the development in the cheek pouch of the Syrian hamster of a transplantable hypernephroma from human origin can be strongly retarded by tetracyclines as well. Therefore, the mitochondrial genetic system has to be reckoned as a target for chemotherapy and tetracyclines as cytostatic agents.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6518450     DOI: 10.1016/s0304-3835(84)80023-3

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

1.  Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines.

Authors:  M Tolomeo; S Grimaudo; S Milano; M La Rosa; V Ferlazzo; G Di Bella; C Barbera; D Simoni; P D'Agostino; E Cillari
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones.

Authors:  E E McKee; M Ferguson; A T Bentley; T A Marks
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

3.  Ultrastructure and dynamics of selective mitochondrial injury in carcinoma cells after doxycycline photosensitization in vitro.

Authors:  C R Shea; D Whitaker; G F Murphy; T Hasan
Journal:  Am J Pathol       Date:  1988-11       Impact factor: 4.307

Review 4.  Mitochondrial ribosomes in cancer.

Authors:  Hyun-Jung Kim; Priyanka Maiti; Antoni Barrientos
Journal:  Semin Cancer Biol       Date:  2017-04-23       Impact factor: 15.707

Review 5.  Local anti-angiogenic brain tumor therapies.

Authors:  E P Sipos; H Brem
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

6.  Influence of chemically modified tetracyclines on proliferation, invasion and migration properties of MDA-MB-468 human breast cancer cells.

Authors:  Q Meng; J Xu; I D Goldberg; E M Rosen; R A Greenwald; S Fan
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

7.  Activation of c-Jun N-terminal kinase is essential for mitochondrial membrane potential change and apoptosis induced by doxycycline in melanoma cells.

Authors:  Jiunn-Min Shieh; Tur-Fu Huang; Chi-Feng Hung; Kuan-Hsien Chou; Yih-Jeng Tsai; Wen-Bin Wu
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

8.  Peptide deformylase inhibitors as potent antimycobacterial agents.

Authors:  Jeanette W P Teo; Pamela Thayalan; David Beer; Amelia S L Yap; Mahesh Nanjundappa; Xinyi Ngew; Jeyaraj Duraiswamy; Sarah Liung; Veronique Dartois; Mark Schreiber; Samiul Hasan; Michael Cynamon; Neil S Ryder; Xia Yang; Beat Weidmann; Kathryn Bracken; Thomas Dick; Kakoli Mukherjee
Journal:  Antimicrob Agents Chemother       Date:  2006-09-11       Impact factor: 5.191

9.  Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma.

Authors:  James L Frazier; Paul P Wang; Daniel Case; Betty M Tyler; Gustavo Pradilla; Jon D Weingart; Henry Brem
Journal:  J Neurooncol       Date:  2003-09       Impact factor: 4.130

10.  NF-kappaB and AP-1 connection: mechanism of NF-kappaB-dependent regulation of AP-1 activity.

Authors:  Shuichi Fujioka; Jiangong Niu; Christian Schmidt; Guido M Sclabas; Bailu Peng; Tadashi Uwagawa; Zhongkui Li; Douglas B Evans; James L Abbruzzese; Paul J Chiao
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.